TBCRC 047: Innovative Combination Immunotherapy for Metastatic Triple-Negative Breast Cancer (H-46124)
Description
Content
The purpose of this study is to determine if the investigational combination of avelumab with several different drugs - utomilumab, PF-04518600 or binimetinib - is safe and effective for treating patients with metastatic triple-negative breast cancer.
Contact
Phone 1: 713–798–1911
IRB: H-46124
Status:
Active
Created:
